69 results about "Cycloserine" patented technology

Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and / or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:whereinR1 and R2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR5;or R1 and R2, taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group;X and Y are independently selected from O, S, NH, and (CR6R7)n;R3 is hydrogen, alkyl or M+;M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof;Z is N or CR4;R4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR5;R5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl;R6 and R7 are independently selected from hydrogen and alkyl;n is an integer from 1 to 6;at least one of R1, R2 and R4 is other than hydrogen; andat least one of X and Y is (CR6R7)n.D-serine or cycloserine may be coadministered along with the compound of formula I.

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Disclosed are culture media, protocols and kits for diagnosis of toxigenic Clostridium difficile, where the culture medium comprises Cooked Meat Medium with glucose; yeast extract; taurocholate; cycloserine; and cefoxitin.

Disclosed are culture media, protocols and kits for diagnosis of toxigenic Clostridium difficile, where the culture medium comprises Cooked Meat Medium with glucose; yeast extract; taurocholate; cycloserine; and cefoxitin.

Van A and Van B vancomycin resistant enterococci detection media as well as a method of selectively detecting Van A and Van B vancomycin resistant enterococci clinically important in vancomycin resistant enterococci from testing microorganisms or specimens using the media. The media for selectively detecting Van A and Van B VRE from testing microorganisms and specimens are media where enterococci can grow where vancomycin, D-cycloserine and D-lactate are added. Preferably 32-256 μg / ml of vancomycin, 1-64 μg / ml of D-cycloserine, and 0.025-0.8 mol / l of sodium lactate are added to culture medium where enterococci can grow.

The invention discloses application of three compounds extracted from starfish to the promotion of bone fracture healing, and a preparation method for the three compounds, and belongs to the field of methods for extracting Chinese medicines. The preparation method for the three compounds comprises the following steps of: crushing a starfish medicinal material, extracting by using a solvent, mixing extracting solutions, concentrating under reduced pressure, and drying to obtain a total extract; performing equal-volume extraction on the total extract by using ethyl acetate and n-butanol to obtain an n-butanol layer and an ethyl acetate layer; separating the ethyl acetate layer by a silicagel column, and purifying to obtain the compound 3, namely ergosta-7,22-diene-3beta,5,6-triol and the compound 1, namely cyclo(leucine-proline)dipeptide; and separating the n-butanol layer by the silicagel column to obtain the compound 2, namely cyclo(serine-leucine)dipeptide. The compounds have a good effect of promoting bone fracture healing, so that the application prospect of the three compounds used as novel medicines for promoting bone fracture healing is showed.

Van A and Van B vancomycin resistant enterococci detection media as well as a method of selectively detecting Van A and Van B vancomycin resistant enterococci clinically important in vancomycin resistant enterococci from testing microorganisms or specimens using the media. The media for selectively detecting Van A and Van B VRE from testing microorganisms and specimens are media where enterococci can grow where vancomycin, D-cycloserine and D-lactate are added. Preferably 32-256 mug / ml of vancomycin, 1-64 mug / ml of D-cycloserine, and 0.025-0.8 mol / l of sodium lactate are added to culture medium where enterococci can grow.

The invention relates to the technical field of pseudomonas aeruginosa detection and discloses a pseudomonas aeruginosa chromogenic culture medium and a method for quick detection by the same. The pseudomonas aeruginosa chromogenic culture medium comprises a basic medium, a chromogenic substrate and an antibacterial agent. The chromogenic substrate comprises 2,3,5-phenyl tetrazolium chloride, 4-methyl umbelliferone-D-glucuronide, and the antibacterial agent comprises nalidixic acid, cycloserine and bile salt. 2,3,5-phenyl tetrazolium chloride acts on a pseudomonas aeruginosa metabolite to showa red color; 4-methyl umbelliferone-D-glucuronide acts on pseudomonas aeruginosa to show fluorescence under a 366nm ultraviolet lamp; by joint action of 2,3,5-phenyl tetrazolium chloride and the antibacterial agent, growth of common disturbance bacteria can be inhibited, and false positive results are avoided. By adoption of the pseudomonas aeruginosa quick detection method, detection and count of pseudomonas aeruginosa can be finished in 24h, and time saving, labor saving, stability, reliability and high sensitivity are realized.

The slow released compound antituberculotic preparation containing synergist is implanting agent or slow released injection comprising slow released microsphere and solvent. The slow released microsphere consists of slow releasing supplementary material, at least one antituberculotic selected from rifampicin, isoniazid and pyrazinamide and at least one antituberculotic synergist selected from cycloserine, ofloxacin, ciprofloxacin, sparfloxacin and capreomycin. The solvent is special solvent containing suspending agent carboxymethyl cellulose, etc. and with viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released compound antituberculotic preparation can release antituberculotic in the local tubercolosis part for 30-40 days so as to maintain the local effective medicine concentration while lowering systemic toxicity. The present invention has obvious unique treating effect on various kinds of intractable tuberulosis.

The invention particularly provides a kit and a method for detecting antituberculous drugs and metabolites thereof in a sample. The kit is used for detecting antituberculous drugs and metabolites thereof in a sample, and comprises a calibration product, a quality control product, an instrument quality control product and an isotope internal standard product, both the calibration material and the quality control material contain rifampicin, isoniazide, rifapentine, pyrazinamide, ethambutol, clofazimine, cycloserine, moxifloxacin, levofloxacin, linezolid, acetyl isoniazide, bedaquiline and deacetylrifampicin; the instrument quality control product comprises a methanol solution containing rifampicin, isoniazid, rifapentine, pyrazinamide, ethambutol, clofazimine, cycloserine, moxifloxacin, levofloxacin, linezolid, acetyl isoniazid, bedaquiline and deacetylrifampicin; the isotope internal standard substance contains an internal standard substance corresponding to a substance contained in the calibrator. The kit disclosed by the invention can be used for detecting the concentrations of the antituberculous drugs and metabolites thereof in various sample types.

Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and / or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors.

In the first variant, the pharmaceutical composition comprises antibiotic and prebiotic in the form of oligosaccharide of a group comprising fructooligosaccharides, galactooligosaccharides, maltooligosaccharides and isomaltooligosaccharides the polymerisation degree of which ranges from 2 to 10, the particle size is equal to less than 0.3 mm and the purity is of at least 95%, wherein the antibiotic particle size ranges from 20 to 200 mkm and the antibiotic and oligosaccharide are contained with a mass ratio ranging from 1:1 to 1:100 respectively. In the second variant, the pharmaceutical composition comprises antibiotic which is in the form of a powder with the particle size ranging from 20 t0 200 mkm and is selected form a group consisting of beta-lactams, including the combination thereof with bacterial betalactamase inhibitors, azalides, fluoroquinalones, amphenicols, glycopeptides, ansamycins, nitrofurans, phosphonic acid derivatives, cycloserine and trimetoprim. The prebiotic is in the form of a powder oligosaccharide, the polymerisation degree of which ranges from 2 to 10, the particle size is equal to less than 0.3 mm and the purity is of at least 95%, wherein the antibiotic and oligosaccharide are contained with a mass ratio ranging from 1:1 to 1:100 respectively. The above-mentioned compositions are used for preventing intestinal dysbiosis during antibiotic therapy and are perorally administered. The inventive composition produces a stimulating effect on intestinal lactobacilli and bifidobacteria simultaneously inhibiting the growth and proliferation of extraneous or pathogenic microflora.